The CytospongeTM is a “pill-on-a-string” less invasive alternative to endoscopy which has been developed primarily for the diagnosis of Barrett’s oesophagus, a precursor to oesophageal adenocarcinoma. It was developed by the Fitzgerald Lab, at the University of Cambridge MRC Cancer Unit in the UK. Together with this Cambridge team, CytoSCCAPE is investigating the potential of using the Cytosponge in East Africa for both aetiologic and early-detection research.
As a first step in this development, we have conducted a feasibility study to assess acceptability of the Cytosponge in an asymptomatic community setting. The first 100 sponges were administered in Moshi, Tanzania, during September 2019-January 2020.